MannKind Co. (MNKD) Given a $1.00 Price Target by Piper Jaffray Companies Analysts


The brokerage currently has a "sell" rating on the biopharmaceutical company's stock. Piper Jaffray Companies' target price indicates a potential downside of 10.71% from the stock's current price.



from Biotech News